» Articles » PMID: 26282428

Multicenter Study of Epidemiological Cutoff Values and Detection of Resistance in Candida Spp. to Anidulafungin, Caspofungin, and Micafungin Using the Sensititre YeastOne Colorimetric Method

Abstract

Neither breakpoints (BPs) nor epidemiological cutoff values (ECVs) have been established for Candida spp. with anidulafungin, caspofungin, and micafungin when using the Sensititre YeastOne (SYO) broth dilution colorimetric method. In addition, reference caspofungin MICs have so far proven to be unreliable. Candida species wild-type (WT) MIC distributions (for microorganisms in a species/drug combination with no detectable phenotypic resistance) were established for 6,007 Candida albicans, 186 C. dubliniensis, 3,188 C. glabrata complex, 119 C. guilliermondii, 493 C. krusei, 205 C. lusitaniae, 3,136 C. parapsilosis complex, and 1,016 C. tropicalis isolates. SYO MIC data gathered from 38 laboratories in Australia, Canada, Europe, Mexico, New Zealand, South Africa, and the United States were pooled to statistically define SYO ECVs. ECVs for anidulafungin, caspofungin, and micafungin encompassing ≥97.5% of the statistically modeled population were, respectively, 0.12, 0.25, and 0.06 μg/ml for C. albicans, 0.12, 0.25, and 0.03 μg/ml for C. glabrata complex, 4, 2, and 4 μg/ml for C. parapsilosis complex, 0.5, 0.25, and 0.06 μg/ml for C. tropicalis, 0.25, 1, and 0.25 μg/ml for C. krusei, 0.25, 1, and 0.12 μg/ml for C. lusitaniae, 4, 2, and 2 μg/ml for C. guilliermondii, and 0.25, 0.25, and 0.12 μg/ml for C. dubliniensis. Species-specific SYO ECVs for anidulafungin, caspofungin, and micafungin correctly classified 72 (88.9%), 74 (91.4%), 76 (93.8%), respectively, of 81 Candida isolates with identified fks mutations. SYO ECVs may aid in detecting non-WT isolates with reduced susceptibility to anidulafungin, micafungin, and especially caspofungin, since testing the susceptibilities of Candida spp. to caspofungin by reference methodologies is not recommended.

Citing Articles

Evaluation of Etest and MICRONAUT-AM Assay for Antifungal Susceptibility Testing of : Underestimation of Fluconazole Resistance by MICRONAUT-AM and Overestimation of Amphotericin B Resistance by Etest.

Asadzadeh M, Ahmad S, Alfouzan W, Al-Obaid I, Spruijtenburg B, Meijer E Antibiotics (Basel). 2024; 13(9).

PMID: 39335013 PMC: 11428412. DOI: 10.3390/antibiotics13090840.


Commercial Methods for Antifungal Susceptibility Testing of Saprophytic Molds: Can They Be Used to Detect Resistance?.

Paranos P, Espinel-Ingroff A, Meletiadis J J Fungi (Basel). 2024; 10(3).

PMID: 38535222 PMC: 10971485. DOI: 10.3390/jof10030214.


Molecular Characterization and Sterol Profiles Identify Nonsynonymous Mutations in as a Major Mechanism Conferring Reduced Susceptibility to Amphotericin B in Candida kefyr.

Asadzadeh M, Alfouzan W, Parker J, Meis J, Kelly S, Joseph L Microbiol Spectr. 2023; 11(4):e0147423.

PMID: 37358415 PMC: 10434000. DOI: 10.1128/spectrum.01474-23.


Overestimation of Amphotericin B Resistance in Candida auris with Sensititre YeastOne Antifungal Susceptibility Testing: a Need for Adjustment for Correct Interpretation.

Siopi M, Peroukidou I, Beredaki M, Spruijtenburg B, de Groot T, Meis J Microbiol Spectr. 2023; 11(3):e0443122.

PMID: 37036351 PMC: 10269614. DOI: 10.1128/spectrum.04431-22.


Antifungal Activity of Essential Oil against : Time-Kill Study on Pediatric Sputum Isolates.

Mijatovic S, Stankovic J, Colovic Calovski I, Dubljanin E, Pljevljakusic D, Bigovic D Molecules. 2022; 27(19).

PMID: 36234837 PMC: 9571381. DOI: 10.3390/molecules27196300.


References
1.
Guinea J, Zaragoza O, Escribano P, Martin-Mazuelos E, Peman J, Sanchez-Reus F . Molecular identification and antifungal susceptibility of yeast isolates causing fungemia collected in a population-based study in Spain in 2010 and 2011. Antimicrob Agents Chemother. 2013; 58(3):1529-37. PMC: 3957835. DOI: 10.1128/AAC.02155-13. View

2.
Barnes P, Marr K . Risks, diagnosis and outcomes of invasive fungal infections in haematopoietic stem cell transplant recipients. Br J Haematol. 2007; 139(4):519-31. DOI: 10.1111/j.1365-2141.2007.06812.x. View

3.
Costa-de-Oliveira S, Pina-Vaz C, Mendonca D, Goncalves Rodrigues A . A first Portuguese epidemiological survey of fungaemia in a university hospital. Eur J Clin Microbiol Infect Dis. 2008; 27(5):365-74. DOI: 10.1007/s10096-007-0448-4. View

4.
Eschenauer G, Nguyen M, Shoham S, Vazquez J, Morris A, Pasculle W . Real-world experience with echinocandin MICs against Candida species in a multicenter study of hospitals that routinely perform susceptibility testing of bloodstream isolates. Antimicrob Agents Chemother. 2014; 58(4):1897-906. PMC: 4023707. DOI: 10.1128/AAC.02163-13. View

5.
Espinel-Ingroff A, Pfaller M, Bustamante B, Canton E, Fothergill A, Fuller J . Multilaboratory study of epidemiological cutoff values for detection of resistance in eight Candida species to fluconazole, posaconazole, and voriconazole. Antimicrob Agents Chemother. 2014; 58(4):2006-12. PMC: 4023759. DOI: 10.1128/AAC.02615-13. View